Acute Leukemia Clinical Trials

23 studies are recruiting for acute leukemia in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing

   This study aims to test the Tools for Reducing Inequity in Acute Leukemia (TRIAL) web-based application that is designed to support participants with acute leukemia by providing information and resources about leukemia and clinical trial participation.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT06907797 on ClinicalTrials.gov

2. A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

   The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of bleximenib in phase 1 Part 1 (Dose Escalation) and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion). The purpose of the Phase 2 part of the study is to evaluate the efficacy of …

   Stage

   Phase 1

   Ages

   2 and older

   Site

   City of Hope, Duarte, California

   Locations

   102 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT04811560 on ClinicalTrials.gov

3. Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation

   Study of QUAIL-100 in Patients With High Risk Acute Leukemia and Myelodysplastic Syndrome Who Have Received Hematopoietic Stem Cell Transplant

   Stage

   Phase 1

   Ages

   1 to 39

   Site

   Lucille Packard Children's Hospital of Stanford University, Palo Alto, California

   Run by

   Laguna Biotherapeutics, Inc.

   See if you can join NCT07573111 on ClinicalTrials.gov

4. Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

   The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Banner MD Anderson Cancer Center, Gilbert, Arizona

   Locations

   45 in total

   Run by

   Kura Oncology, Inc.

   See if you can join NCT06001788 on ClinicalTrials.gov

5. Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies

   This phase 1 trial will investigate the safety and effectiveness of Thiotepa, Busulfan, and Fludarabine (TBF) conditioning regimen with post-transplant cyclophosphamide (PTCy) in HLA-matched related or unrelated donor allogeneic stem cell transplantation (alloSCT).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UMPC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Run by

   Sawa Ito, MD

   See if you can join NCT07565220 on ClinicalTrials.gov

6. Strength Training Exercise in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (STEP-ALL)

   Acute lymphoblastic leukemia (ALL) is the most common cancer in children and, along with lymphoblastic lymphoma, represents the most common group of childhood lymphoid malignancies. Survival rates have improved over the years, but many children still experience long-term side effects from treatment…

   Stage

   Not phased

   Ages

   6 and older

   Site

   University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT07634653 on ClinicalTrials.gov

7. Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia

   The investigators are doing this research study to assess the percentage of patients receiving stem cell transplantation for the type of blood cancer you have. They want to know how many patients get a transplant and why some patients do get a transplant while others do not. Also they want to explo…

   Stage

   Not phased

   Ages

   18 to 80

   Site

   Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut

   Locations

   3 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT02677064 on ClinicalTrials.gov

8. CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

   The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections. T depletion of the donor hematopoietic stem cell graft is effective in preventing GVHD, but immune reconst…

   Stage

   Not phased

   Ages

   Up to 25

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Run by

   Children's Hospital of Philadelphia

   See if you can join NCT03810196 on ClinicalTrials.gov

9. Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

   This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVH…

   Stage

   Phase 2

   Ages

   Up to 60

   Site

   Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

   Run by

   Masonic Cancer Center, University of Minnesota

   See if you can join NCT03314974 on ClinicalTrials.gov

10. A Study of Revumenib and Mezigdomide in People With Leukemia

    The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.

    Stage

    Phase 1

    Ages

    12 and older

    Site

    Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey

    Locations

    10 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07356154 on ClinicalTrials.gov

11. Familial Investigations of Childhood Cancer Predisposition

    NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor …

    Stage

    Not phased

    Ages

    Any age

    Site

    St. Jude Children's Research Hospital, Memphis, Tennessee

    Run by

    St. Jude Children's Research Hospital

    See if you can join NCT03050268 on ClinicalTrials.gov

12. Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

    This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies). Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth …

    Stage

    Phase 2

    Ages

    0 and older

    Site

    Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

    Run by

    Fred Hutchinson Cancer Center

    See if you can join NCT04195633 on ClinicalTrials.gov

13. MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

    This is a Phase II study following subjects proceeding with Treosulfan (36g/m2) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion, with post-transplant cyclophosphamide (PTCy) at 40mg/kg, tacrolimus and MMF for GVHD prophylaxis.

    Stage

    Phase 2

    Ages

    2 to 75

    Site

    Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

    Run by

    Masonic Cancer Center, University of Minnesota

    See if you can join NCT07493538 on ClinicalTrials.gov

14. BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)

    This study is being done to see if the addition of a targeted form of radiation to standard conditioning regimen will increase the amount of cancer cells that are killed off in the bone marrow and reduce the chances that your disease may return. This description is called Intensity Modulated Total …

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    University of Illinois Cancer Center, Chicago, Illinois

    Run by

    University of Illinois at Chicago

    See if you can join NCT04187105 on ClinicalTrials.gov

15. MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

    This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies. This is a safety/feasibility study of the investigational procedure/product.

    Stage

    Phase 2

    Ages

    Up to 60

    Site

    University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota

    Run by

    Masonic Cancer Center, University of Minnesota

    See if you can join NCT05735717 on ClinicalTrials.gov

16. Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)

    This is a randomized phase II trial of standard-of-care reduced-intensity conditioning (RIC) with 200 versus 400 cGy of total body irradiation (TBI) in patients with acute leukemia undergoing first allogeneic blood or marrow Transplantation (BMT). The primary objective is to compare the rates of gr…

    Stage

    Not phased

    Ages

    Any age

    Site

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

    Run by

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT06803745 on ClinicalTrials.gov

17. A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

    The purpose of this study is to learn more about LP-118 (an experimental drug) and its side effects and decide on acceptable doses. The purpose of this study is to determine if LP-118 can be given safely with another medicine called ponatinib, that is FDA-approved for the treatment of acute lymphob…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois

    Locations

    2 in total

    Run by

    University of Chicago

    See if you can join NCT06207123 on ClinicalTrials.gov

18. Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

    This phase II trial investigates two strategies and how well they work for the reduction of graft versus host disease in patients with acute leukemia or MDS in remission. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cel…

    Stage

    Phase 2

    Ages

    1 to 60

    Site

    Moffitt Cancer Center, Tampa, Florida

    Locations

    3 in total

    Run by

    Fred Hutchinson Cancer Center

    See if you can join NCT03970096 on ClinicalTrials.gov

19. Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant

    This phase I trial tests the safety, side effects, best dose and effectiveness of revumenib in treating patients with acute leukemia after allogeneic stem cell transplant. Revumenib is in a class of medications called menin inhibitors. Revumenib targets and binds to the protein menin, thereby preve…

    Stage

    Phase 1

    Ages

    2 and older

    Site

    City of Hope Medical Center, Duarte, California

    Run by

    City of Hope Medical Center

    See if you can join NCT06575296 on ClinicalTrials.gov

20. Umbilical Cord Blood Transplantation From Unrelated Donors

    This study is being done to determine how long it takes for the engraftment (recovery of blood cell counts) of umbilical cord stem cells and also how often engraftment of umbilical cord stem cells transplanted from an unrelated donor fails. Another purpose will be to document the rate of disease-fr…

    Stage

    Not phased

    Ages

    0 to 75

    Site

    Wilmot Cancer Institute, Rochester, New York

    Run by

    University of Rochester

    See if you can join NCT03016806 on ClinicalTrials.gov

21. Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant

    In an effort to reduce graft versus host disease (GVHD) and enhance graft versus leukemia (GVL) effect post allogenic hematopoietic stem cell transplantation (AHSCT), recent research has focused on host immune cell depletion. Frame shifting anti-thymocyte globulin (ATG) backwards to earlier days be…

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Run by

    University of Alabama at Birmingham

    See if you can join NCT06265584 on ClinicalTrials.gov

22. Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant

    The purpose of this study is to test whether the combination of the drugs called tacrolimus (Tac), methotrexate (MTX) and new dosing strategy of another drug called (rabbit Anti-thymocyte Globulin [ATG]) will help prevent the development and/or improve severity of acute and/or chronic GVHD.

    Stage

    Phase 2

    Ages

    18 to 60

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Run by

    University of Alabama at Birmingham

    See if you can join NCT06315309 on ClinicalTrials.gov

23. AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

    Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.

    Stage

    Phase 2

    Ages

    0 to 30

    Site

    New York Medical College, Valhalla, New York

    Run by

    Mitchell Cairo

    See if you can join NCT04099966 on ClinicalTrials.gov